Primary sclerosing cholangitis

Hepatology

Volumn 30, Issue 1, 1999, Pages 325-332

  Angulo, Paul ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; HLA ANTIGEN; METRONIDAZOLE; TUMOR NECROSIS FACTOR;

ANTIBIOTIC THERAPY; ARTICLE; AUTOIMMUNITY; BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; BONE DISEASE; CHOLESTASIS; COLORECTAL CANCER; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; ENTERITIS; GENETIC PREDISPOSITION; HLA SYSTEM; LIVER TRANSPLANTATION; PATHOGENESIS; PORTAL HYPERTENSION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING;

BONE DISEASES, METABOLIC; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGITIS, SCLEROSING; HUMANS; HYPERTENSION, PORTAL; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PROGNOSIS;

EID: 0033002048     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300101     Document Type: Article

References (23)

1. Lee YM, Kaplan M. Primary sclerosing cholangitis. N Engl J Med 1995;332:924-933.
2. Porayko MK, Wiesner RH, LaRusso NF, Ludwig J, MacCarty RL, Steiner BL, Twomey CK, et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990;98:1594-1602.
3. Angulo P, DeSotel CK, Gershwin ME, Shoenfeld Y, Ahmed A, Peter J, Lindor KD. The profile and significance of serum autoantibodies in primary sclerosing cholangitis [Abstract]. HEPATOLOGY 1998;28:444A.
4. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980;21:870-877
5. Boberg KM, Schrumpf E, Fausa O, Elgjo K, Kolmannskog F, Haaland T, Hotler E. Hepatobiliary disease in ulcerative colitis. An analysis of 18 patients with hepatobiliary lesions classified as small-duct primary sclerosing cholangitis. Scand J Gastroenterol 1994;29:144-752.
6. Duer RH, Targan SR, Landers CJ, LaRusso NF, Lindsay KL, Wiesner RH, Schanahan E Neutrophil cytoplasmic antibodies: a link between sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991;100:1385-1391
7. Klein R, Eisenburg J, Weber P, Seibold F, Berg PA. Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis. HEPATOLOGY 1991;14:1147-1152
8. Mulder AHL, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CGM. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. HEPATOLOGY 1993;17:411-417.
9. Senaldi G, Donaldson PT, Magrin S, Farrant JM, Alexander GJM, Vergani D, Williams R. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology 1989;97:1430-1434
10. Bodenheimer HC, LaRusso NF, Thayer WR Jr, Charland C, Staples PJ, Ludwig J. Elevated circulating immune complexes in primary sclerosing cholangitis. HEPATOLOGY 1983;3:150-154
11. Minuk GY, Angus M, Brickman CM, Lawley TJ, Frank MM, Hoofnagle JH, Jones EA. Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroenterology 1985;88:166-170.
12. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990;98:464-469.
13. Farrant JM, Doherty DG, Donaldson PT, Vaughan RW, Hayllar KM, Weish KI, Eddleston AL, et al. Amino acid substitutions at positions 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. HEPATOLOGY 1992;16:390-395.
14. Mehal WZ, Lo Y-MD, Wordsworth BP, Nauberger JM, Hubscher SC, Fleming KA, Chapman RW. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1994;106:160-167.
15. Olerup O, Olsson R, Hultcrantz R, Broome U. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995;108:870-878.
16. Aguilar HI, Nuako K, Krom RAF, Wiesner RH. Do primary sclerosing cholangitis (PSC) patients who express HLA-DR4 haplotype have a more rapidly progressive disease? [Abstract]. HEPATOLOGY 1994;20:154A.
17. Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. HEPATOLOGY 1991;13:766-772.
18. Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest 1992;90:1313-1322.
19. Nolan JP. Intestinal endotoxins as mediators of hepatic injury - an idea whose time has come again. HEPATOLOGY 1989;10:887-891.
20. Angulo P, Pearce DH, Johnson CD, Boynton JJ, Petersen BT, LaRusso NF, Lindor KD. Magnetic resonance cholangiopancreatogreaphy in the evaluation of the biliary tree [Abstract]. HEPATOLOGY 1998;28:308A.
21. Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991;11:11-17.
22. El-Shabrawi M, Wilkinson ML, Portmann B, Mieli-Vergani G, Chong SK, Williams R, Mowat AP. Primary sclerosing cholangitis in childhood. Gastroenterology 1987;92:1226-1235.
23. Wilschanski M, Chait P, Wade JA, Davis L, Corey M, St. Louis P, Griffiths AM, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. HEPATOLOGY 1995;22:1415-1422.